Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch
-- LP-184 Phase 1a clinical trial results demonstrate all primary
endpoints achieved with 48% clinical benefit rate in evaluable cancer
patients at or above therapeutic dose threshold; marked tumor reductions
observed in patients with DNA damage repair mutations including CHK2, ATM,
and STK11/KEAP1 alterations.
-- FDA Type C meeting completed, providing regulatory guidance and pathway
clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in
Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone
combination strategy.
-- LP-300 preliminary Phase 2 data presented from the HARMONIC$(TM)$ trial
at the 66th Annual Meeting of the Japan Lung Cancer Society with further
clinical and patient data planned for a webinar in December.
-- LP-284 clinical data showcased at 25th Annual Lymphoma, Leukemia &
Myeloma (LL&M) Congress, generating interest from the biopharma and
clinical communities and initiating discussions for combination therapy
potential.
-- KOL-hosted scientific webinar on LP-184 Phase 1a results scheduled for
November 20, 2025 at 4:30 p.m. ET, providing insights from key opinion
leader at Fox Chase Cancer Center along with additional clinical data and
future plans from Lantern management.
-- Precision, biomarker-driven development strategy strengthened by
Phase1a data, positioning LP-184 for targeted Phase 1b/2 trials in TNBC,
NSCLC with KEAP1/STK11 mutations, bladder cancer, and first recurrent
GBM--indications representing combined market potential exceeding $7
billion annually.
-- AI platform commercial readiness demonstrated at inaugural AI for
Biology and Medicine symposium, showcasing RADR$(R)$ platform modules as
deployable tools for biopharma partners.
-- Disciplined capital management maintained with approximately $12.4
million in cash, cash equivalents, and marketable securities as of
September 30, 2025, providing expected operating runway into
approximately Q3 2026.
-- C onference call and webcast scheduled for Thursday, November 13, 2025
at 9:00 a.m. ET.
DALLAS--(BUSINESS WIRE)--November 13, 2025--
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR(R) artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the third quarter 2025 ended September 30, 2025, and provided an update on its portfolio of AI-driven drug candidates and AI platform, RADR(R) .
"The third quarter represented a transformational period for Lantern Pharma as we announced successful enrollment completion of our LP-184 Phase 1a trial, achieving all primary endpoints with unique clinical benefit observations in multiple hard-to-treat solid tumors," said Panna Sharma, CEO & President of Lantern Pharma. "The observed 48% clinical benefit rate at or above the therapeutic dose threshold, combined with the favorable safety profile and clear biomarker signals, validates our AI-driven, precision medicine approach and positions us to advance multiple planned high-value Phase 1b/2 trials. Simultaneously, our productive FDA Type C meeting provides a clear regulatory pathway for our pediatric CNS cancer program under our subsidiary Starlight Therapeutics. Additionally, the interest generated for LP-284 at the LL&M Congress underscores the commercial potential across our pipeline. We are executing with discipline and focus as we advance toward pivotal value-creation milestones in multiple oncology indications."
Clinical Pipeline Developments
LP-184: Detailed Phase 1a Results Demonstrate Clinical Proof-of-Concept & Activity
In September, Lantern announced the completion of enrollment and initial clinical results from its LP-184 Phase 1a clinical trial (NCT05933265), which successfully achieved all primary endpoints. The data across the 63 patients enrolled provided critical insights into safety, pharmacokinetics, biomarker correlations, and clinical activity that position LP-184 for advancement into targeted planned Phase 1b/2 studies.
Highlights of the Phase 1a Results:
-- Clinical Benefit and Activity: The trial demonstrated clinical benefit
in 48% of evaluable cancer patients treated at or above the therapeutic
dose threshold. This encouraging activity was observed in heavily
pretreated patients who had exhausted available standard-of-care
therapies, representing proof-of-concept for LP-184's synthetic lethal
mechanism.
-- Safety Profile Supports Broad Development: LP-184 demonstrated a
favorable safety and tolerability profile with minimal dose-limiting
toxicities. The safety data support advancement into both monotherapy and
combination therapy approaches with PARP inhibitors and immunotherapy
agents.
-- Activity in Difficult-to-Treat Cancers: Notable clinical benefits were
observed in historically challenging tumor types including glioblastoma
multiforme (GBM), gastrointestinal stromal tumor (GIST), and thymic
carcinoma. Several patients have continued treatment beyond enrollment
completion due to ongoing clinical benefit.
-- Biomarker Strategy Strengthened: A key finding from the Phase 1a trial
was the observation of marked tumor reductions in patients harboring
specific DNA damage repair mutations, including CHK2, ATM, BRCA1, and
STK11/KEAP1 alterations. These biomarker insights directly validate the
AI-driven patient stratification approach developed through Lantern's
RADR(R) platform and support the use of genomic selection criteria in
future trials.
-- Pharmacokinetics Enable Dose Optimization: The trial successfully
characterized LP-184's pharmacokinetic profile and established the
recommended Phase 2 dose (RP2D) of 0.39 mg/kg, providing clear dosing
guidance for planned Phase 1b/2 studies across multiple indications.
Based on the Phase 1a results and biomarker insights, Lantern is advancing development plans for LP-184 in three high-value indications:
-- Triple-Negative Breast Cancer (TNBC), which represents a potential
annual market opportunity exceeding $4 billion.
-- NSCLC with STK11/KEAP1 Co-mutations: Phase 1b/2 study in a
biomarker-defined subset of patients with mutations in STK11 and/or KEAP1
genes, representing a significant unmet medical need and a potential
annual market approaching $1.5 billion.
-- Bladder Cancer with DNA damage repair mutations in patients who have
relapsed from SOC (standard of care) therapies, which is planned to be an
investigator-led study initiating in Denmark.
Comprehensive results from the LP-184 Phase 1a trial are being prepared for submission to peer-reviewed journals and presentation at major oncology conferences. To provide additional insights and expert analysis of the clinical data, Lantern will host a Key Opinion Leader $(KOL)$-hosted scientific webinar on November 20, 2025 at 4:30 p.m. Eastern Time featuring detailed discussion of the Phase 1a results, biomarker findings, and clinical development strategy.
FDA Type C Meeting: Clarity in Regulatory Path for Pediatric CNS Cancer Program
A major third quarter regulatory milestone was the successful completion of a Type C meeting with the U.S. Food and Drug Administration during September. This meeting provided important guidance on the regulatory pathway and trial design for Starlight Therapeutics' -- a wholly owned subsidiary of Lantern Pharma -- planned pediatric clinical trial focused on CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA provided constructive and supportive feedback on the proposed clinical trial structure.
Key outcomes from the Type C meeting included:
-- Parallel ATRT Cohort Supported: The FDA confirmed support for a
parallel cohort design specifically for ATRT patients, which will
accelerate data collection in this ultra-rare pediatric population while
maintaining statistical rigor.
-- Combination Strategy Confirmed: The agency confirmed the potential
incorporation of spironolactone as a combination agent with
LP-184/STAR-001. This combination strategy is based on preclinical data
demonstrating synergistic activity and RADR(R) platform predictions of
enhanced efficacy in pediatric brain tumors.
-- Trial Design Alignment: The FDA provided guidance on appropriate
endpoints, patient selection criteria, and safety monitoring approaches
for this vulnerable pediatric population, enabling Starlight Therapeutics
to finalize the clinical protocol with confidence in the regulatory
pathway.
Regulatory Designations and Market Opportunity:
-- LP-184, which is being developed as STAR-001 by Starlight Therapeutics
in CNS cancers, has received both Rare Pediatric Disease Designation and
Orphan Drug Designation from the FDA for ATRT, along with additional Rare
Pediatric Disease Designations for hepatoblastoma, rhabdomyosarcoma, and
malignant rhabdoid tumors. These designations underscore the urgent unmet
need for innovative therapies in aggressive pediatric cancers and provide
potential pathways for possible priority review vouchers upon approval.
-- ATRT is an ultra-rare pediatric brain tumor with the genetic hallmark
of SMARCB1 gene loss or dysfunction, affecting primarily children under
age 3. Current treatment options are limited and associated with
significant long-term toxicities, creating substantial demand for novel
targeted approaches.
LP-300 HARMONIC(TM) Trial: Enrollment and Follow-Up Progress
The Phase 2 HARMONIC(TM) trial continued patient enrollment and follow-up during the third quarter across sites in the United States, Japan, and Taiwan. The trial evaluates LP-300 in combination with standard-of-care chemotherapy (carboplatin + pemetrexed) in never-smokers with NSCLC adenocarcinoma who have progressed after tyrosine kinase inhibitor therapy.
-- In late July, Lantern announced the completion of enrollment in Japan
for the HARMONIC(TM) trial across five clinical sites in Japan, including
the National Cancer Center Tokyo.
-- During November, clinical investigators associated with the
HARMONIC(TM) trial presented data from the ongoing study at the 66th
Annual Meeting of the Japan Lung Cancer Society. Dr. Jonathan Dowell from
UT Southwestern Medical Center presented, "A Phase II Trial of LP-300
plus Carboplatin and Pemetrexed in TKI-Progressed NSCLC Patients". Data
from this presentation included the Asian and US cohorts of the study and
will be further reviewed and presented in December by Lantern Pharma.
-- Also, during the third quarter the company progressed with a change in
clinical staffing and a transition of CRO services in Asia focused on
significant cost reductions and efficiency in Taiwan.
-- The study's strategic positioning in Asia, where never-smokers
represent 33-40% of NSCLC cases compared to approximately 15% in Western
populations, positions Lantern for potential regional partnerships and
co-development opportunities. The treatment of never-smokers with NSCLC
represents an estimated $4+ billion annual market opportunity with no
specifically approved therapies for this patient population.
LP-284: LL&M Congress Presentation & Future Development Plans
During October Lantern presented clinical data from its ongoing LP-284 Phase 1 trial at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York City. The presentation showcased the confirmed complete metabolic response in a heavily pretreated DLBCL patient and highlighted LP-284's novel mechanism of action and combination therapy potential.
LL&M Congress Impact and Additional Milestones:
-- Presentation generated interest from biopharmaceutical companies and
clinical investigators, with ongoing discussions focused on: combination
therapy development with FDA-approved agents; post-immunotherapy
treatment strategies; and LP-284's mechanistic differentiation. LP-284
has demonstrated particular lethality in cells with deficient DNA damage
response, a targetable vulnerability in NHL.
-- Additional clinical sites being recruited with a focus on NHL and
high-grade B-cell lymphoma patients to accelerate enrollment.
-- Partnership and collaboration discussions advancing with emphasis on
combination therapy protocols.
-- Expansion into autoimmune and inflammatory indications under
preclinical evaluation, leveraging LP-284's B-cell depletion activity.
LP-284 benefits from strong intellectual property protection with composition of matter patents granted in the U.S., Europe, Japan, India, and Mexico, providing exclusivity through 2039. The drug candidate has received multiple FDA Orphan Drug Designations including for mantle cell lymphoma and high-grade B-cell lymphomas.
RADR(R) AI Platform: Demonstrating Commercial Value and Industry Leadership
AI for Biology and Medicine Symposium: Showcasing Platform Capabilities
A key highlight of the third quarter was Lantern's presentation at the inaugural AI for Biology and Medicine symposium at the University of North Texas on October 30, 2025. This presentation demonstrated the commercial readiness and real-world applicability of two RADR(R) platform modules. An additional large-scale rollout of a multi-agentic system focused on addressing drug development and research needs in rare cancers that leverages Lantern's unique approach to developing therapies and approaches in rare and orphan cancers is underway. This initiative is planned to be made public during December with broader industry rollout in early 2026.
predictBBB.ai Platform - Best-in-Class BBB Prediction:
-- This ensemble machine learning model achieves 94.1% accuracy for
blood-brain barrier permeability prediction and can screen 200,000
molecular candidates in under one week. Lantern's algorithms currently
hold five of the top eleven positions on the Therapeutic Data Commons
Leaderboard, establishing clear technological leadership.
-- The platform addresses a critical pharmaceutical challenge: only 2-6%
of small-molecule drugs successfully cross the blood-brain barrier. The
BBB technologies market is projected to grow from $1.4 billion in 2023 to
$9.85 billion by 2032, representing significant commercial opportunity.
LBx-AI Liquid Biopsy Platform - Predictive Biomarker Discovery:
-- This AI-powered liquid biopsy analysis platform has achieved 86%
accuracy for predicting treatment response in non-small cell lung cancer
and has demonstrated a 0.76 Pearson correlation for PD-L1 level inference
from circulating tumor DNA analysis. This capability enables non-invasive
patient stratification and real-time treatment monitoring.
-- Lantern has entered into additional collaborations with leading
research and cancer centers to further strengthen and validate this
module in other cancers.
RADR(R) Platform Impact Across Pipeline
The third quarter developments underscore RADR(R) 's central role in Lantern's drug development success:
-- Biomarker Discovery: RADR(R) predictions of LP-184 sensitivity in CHK2,
ATM, and STK11/KEAP1-mutated cancers were validated in the Phase 1a trial,
demonstrating the platform's promise for identifying responsive patient
populations.
-- Combination Therapy Identification: RADR(R) analysis identified
LP-184's synergy with PARP inhibitors and immunotherapy, as well as
LP-284's synergy with rituximab, directly informing clinical development
strategies and partnership discussions.
-- Development Efficiency: On average, Lantern's newly developed AI-guided
drug programs have advanced from initial insights to first-in-human
trials in 2-3 years at approximately $1.0-2.5 million per program,
demonstrating significant cost and time advantages over traditional
development approaches.
Financial Results for Third Quarter 2025
Balance Sheet: Cash, cash equivalents, and marketable securities were approximately $12.4 million as of September 30, 2025, compared to approximately $24.0 million as of December 31, 2024. The company believes that its existing cash, cash equivalents, and marketable securities on hand as of the date of this press release will enable it to fund anticipated operating expenses and capital expenditure requirements into approximately Q3 2026.
Research and Development Expenses: R&D expenses were approximately $2.4 million for the quarter ended September 30, 2025, compared to approximately $3.7 million for the quarter ended September 30, 2024. The decrease was primarily attributable to decreases in research studies and materials of approximately $1,032,000 relating to the conduct and support of clinical trials, decreases in consulting expenses of approximately $55,000 and decreases in payroll and compensation expenses of approximately $224,000. This was partially offset by increases in licensing expenses of approximately $31,000.
General and Administrative Expenses: G&A expenses were approximately $1.9 million for the quarter ended September 30, 2025, compared to approximately $1.5 million for the quarter ended September 30, 2024. The increase was primarily attributable to increases in business development and investor relations expenditures of approximately $321,000, increases in other professional fees of approximately $57,000, and increases in patent costs of approximately $37,000.
Net Loss: Net loss was approximately $4.2 million (or $0.39 per share) for the quarter ended September 30, 2025, compared to a net loss of approximately $4.5 million (or $0.42 per share) for the quarter ended September 30, 2024.
Capitalization: As of September 30, 2025, the Company had approximately 11.0 million shares of common stock outstanding. Options to purchase approximately 1.2 million shares of common stock at a weighted average exercise price of $5.74 per share were outstanding. As of September 30, 2025 there were no warrants outstanding.
In July 2025, the Company entered into an ATM Sales Agreement ("ATM"), with ThinkEquity LLC ("ThinkEquity"), as sales agent, pursuant to which the Company may offer and sell up to $15,530,000 of its common stock from time to time, in "at-the-market" offerings to or through its sales agent. During the quarter ended September 30, 2025, we sold 212,444 shares of common stock under the ATM for the gross proceeds of $989,061. Between October 1, 2025 and the date of this press release, we have sold an additional 144,204 shares of common stock under the ATM for the gross proceeds of $634,333.
Upcoming Milestones and Corporate Developments
Looking ahead to the fourth quarter of 2025 and early 2026, Lantern expects several key value-creation catalysts:
Immediate Near-Term (Q4 2025):
-- November 20, 2025 at 4:30 p.m. ET: KOL hosted scientific webinar on
LP-184 Phase 1a detailed results and clinical development strategy.
-- December 2025: LP-300 further patient follow-up and clinical data.
-- Q4 2025: Continued commercial developments for AI platform modules,
including the multi-agentic system for rare cancer drug development.
Early 2026 Catalysts:
-- Q1 2026: Planned Pediatric CNS cancer trial initiation through
Starlight Therapeutics subsidiary (IND amendment submission)
-- Q1 2026: Planned initiation of LP-184 Phase 1b/2 trials in TNBC and
NSCLC (subject to funding)
-- H1 2026: Investigator-led bladder cancer trial initiation in Denmark
-- 2026: Additional HARMONIC(TM) trial data readouts and potential
partnership announcements
-- Scale up of AI platform commercial efforts
-- Preparation for potential capital formation activities to support
clinical advancement
Conference Call Information
Lantern Pharma will host a conference call and webcast to discuss third quarter 2025 financial results and business updates on Thursday, November 13, 2025 at 9:00 a.m. Eastern Time.
To participate in the conference call, please register at the Zoom webcast link. A replay of the earnings call webcast will be available after the call on the investor relations section of Lantern's website at ir.lanternpharma.com.
KOL-Hosted LP-184 Scientific Webinar: In addition to the earnings call, Lantern will host a scientific webinar featuring key opinion leader analysis of the LP-184 Phase 1a results on November 20, 2025 at 4:30 p.m. Eastern Time. Please register at the Zoom webcast link.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R) , leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate $(ADC)$ program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR(R) platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR(R) platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.
Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek, " "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR(R) AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025.
You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at http://www.lanternpharma.com/ or on the SEC's website at http://www.sec.gov/. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Lantern Pharma Disclosure Channels to Disseminate Information:
Lantern Pharma's investors and others should note that we announce material information to the public about our company and its technologies, clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma's website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations above as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2025 December 31, 2024
------------------ ------------------
(Unaudited)
CURRENT ASSETS
Cash and cash
equivalents $ 8,389,486 $ 7,511,079
Marketable securities 3,973,090 16,501,984
Prepaid expenses and
other current assets 1,098,429 1,234,566
-------------- --------------
Total current assets 13,461,005 25,247,629
Property and equipment,
net 35,977 47,440
Operating lease
right-of-use assets 93,090 239,985
Other assets 36,738 36,738
-------------- --------------
TOTAL ASSETS $ 13,626,810 $ 25,571,792
============== ==============
CURRENT LIABILITIES
Accounts payable and
accrued expenses $ 3,946,018 $ 4,140,361
Operating lease
liabilities, current 93,954 190,814
-------------- --------------
Total current
liabilities 4,039,972 4,331,175
Operating lease liabilities,
net of current portion - 52,843
-------------- --------------
TOTAL LIABILITIES 4,039,972 4,384,018
-------------- --------------
COMMITMENTS AND
CONTINGENCIES (NOTE 4)
STOCKHOLDERS' EQUITY
Preferred Stock
(1,000,000 authorized
at September 30, 2025
and December 31, 2024;
$.0001 par value) (Zero
shares issued and
outstanding at
September 30, 2025 and
December 31, 2024) - -
Common Stock (25,000,000
authorized at September
30, 2025 and December
31, 2024; $.0001 par
value) (11,040,219
shares and 10,784,725
shares issued and
outstanding at
September 30, 2025 and
December 31, 2024,
respectively) 1,104 1,078
Additional paid-in capital 98,616,239 97,058,323
Accumulated other
comprehensive income 40,333 153,990
Accumulated deficit (89,070,838) (76,025,617)
-------------- --------------
Total stockholders' equity 9,586,838 21,187,774
-------------- --------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 13,626,810 $ 25,571,792
============== ==============
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------- ---------------------------
2025 2024 2025 2024
----------- ----------- ------------ ------------
Operating expenses:
General and
administrative $ 1,912,829 $ 1,462,930 $ 5,006,427 $ 4,463,869
Research and
development 2,436,971 3,716,646 8,769,305 11,856,169
---------- ---------- ----------- -----------
Total operating
expenses 4,349,800 5,179,576 13,775,732 16,320,038
---------- ---------- ----------- -----------
Loss from operations (4,349,800) (5,179,576) (13,775,732) (16,320,038)
Interest income 100,921 191,352 365,456 580,962
Other income,
net 71,456 482,527 365,055 833,063
---------- ---------- ----------- -----------
NET LOSS $(4,177,423) $(4,505,697) $(13,045,221) $(14,906,013)
========== ========== =========== ===========
Net loss per share
of common shares,
basic and diluted $ (0.39) $ (0.42) $ (1.21) $ (1.39)
Weighted-average
number of common
shares outstanding,
basic and diluted 10,833,393 10,763,351 10,801,126 10,755,015
View source version on businesswire.com: https://www.businesswire.com/news/home/20251113233259/en/
CONTACT: Investor Contact
Investor Relations
ir@lanternpharma.com
+1-972-277-1136
(END) Dow Jones Newswires
November 13, 2025 08:30 ET (13:30 GMT)
Comments